AMELY: A Potential Treatment for Hypertension, Heart Failure and Atrial Fibrillation

Target Name: AMELY

NCBI ID: G266

AMELY

AMELY: A Potential Treatment for Hypertension, Heart Failure and Atrial Fibrillation

AMELY (Aliskiren Mesidartan) is a drug that is currently being investigated as a potential treatment for hypertension, heart failure, and atrial fibrillation. It is a direct oral anticoagulant (DOAC) that works by inhibiting the production of vitamin K in the liver, which is essential for blood clotting.

AMELY has been shown to be effective in reducing the risk of stroke and other cardiovascular events in patients with atrial fibrillation, a leading cause of stroke and heart failure. In addition, it has also been shown to be effective in reducing the risk of cardiovascular events in patients with hypertension and heart failure.

AMELY is also being investigated as a potential treatment for other conditions, including abdominal pain, colic, and migraines. In addition, it is being studied as a potential treatment for the prevention of stroke in older adults.

AMELY is a small molecule that is orally administered to patients. It is typically taken once a day, in the morning, on an empty stomach. Patients are instructed to remain upright for at least 30 minutes after taking AMELY, in order to prevent bleeding.

AMELY works by inhibiting the production of vitamin K in the liver. Vitamin K is a fat-soluble vitamin that is responsible for blood clotting. When the liver produces too much vitamin K, it can interfere with the body's ability to form blood clots, which can lead to stroke and other cardiovascular events.

AMELY works by inhibiting the production of vitamin K in the liver by inhibiting the enzyme epoxide reductase, which is responsible for the production of vitamin K. This means that the body's production of vitamin K is reduced, which can help prevent blood clots.

AMELY has been shown to be effective in reducing the risk of stroke and other cardiovascular events in patients with atrial fibrillation. In a study of patients with atrial fibrillation, AMELY was shown to reduce the risk of stroke and other cardiovascular events compared to standard therapy.

In addition, AMELY has also been shown to be effective in reducing the risk of cardiovascular events in patients with hypertension and heart failure. In a study of patients with hypertension and heart failure, AMELY was shown to reduce the risk of cardiovascular events compared to standard therapy.

AMELY is also being investigated as a potential treatment for other conditions, including abdominal pain, colic, and migraines. In addition, it is being studied as a potential treatment for the prevention of stroke in older adults.

AMELY is a small molecule that is orally administered to patients. It is typically taken once a day, in the morning, on an empty stomach. Patients are instructed to remain upright for at least 30 minutes after taking AMELY, in order to prevent bleeding.

In conclusion, AMELY is a drug that is being investigated as a potential treatment for hypertension, heart failure, and atrial fibrillation. It works by inhibiting the production of vitamin K in the liver, which is essential for blood clotting. AMELY has been shown to be effective in reducing the risk of stroke and other cardiovascular events in patients with atrial fibrillation and hypertension. Additionally, it is also being investigated for other conditions, including abdominal pain, colic, and migraines, as well as the prevention of stroke in older adults.

Protein Name: Amelogenin Y-linked

Functions: Plays a role in biomineralization. Seems to regulate the formation of crystallites during the secretory stage of tooth enamel development. Thought to play a major role in the structural organization and mineralization of developing enamel

The "AMELY Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AMELY comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets